There are 2949 resources available
283MO - Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
Presenter: Nicholas Turner
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA20 - Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Presenter: Robert Jones
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1022MO - Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients
Presenter: Anders Kverneland
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1237MO - SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
Presenter: Sacha Rothschild
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA21 - Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial
Presenter: Christophe Borg
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
400MO - Curative chemoradiation for low rectal cancer: Early clinical outcomes from a multicentre phase II trial
Presenter: Lars Henrik Jensen
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
401MO - OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial
Presenter: Takayuki Yoshino
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
402MO - Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment
Presenter: Sara Lonardi
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
403MO - Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer
Presenter: Van Morris
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
404MO - Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)
Presenter: Marie-Christine Etienne-Grimaldi
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast